2017 Was the Year We Have Been Waiting For

Abstract

View all access options for this article.

Mendell

, Al-Zaidy

, Shell

, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.

Hirsch

, Rothoeft

, Teig

, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature, 2017; 551:327–332.

Eichler

, Duncan

, Musolino

, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. New Engl J Med, 2017; 377:1630–1638.

Novartis. Press release: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice. https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019 (last accessed November 14, 2017).

Gilead. Press release: Kite's Yescarta™ (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy (last accessed November 14, 2017).

Spark Therapeutics. Press release: FDA Advisory Committee unanimously recommends approval of investigational LUXTURNA™ (voretigene neparvovec) for patients with biallelic RPE65-mediated inherited retinal disease. http://ir.sparktx.com/news-releases/news-release-details/fda-advisory-committee-unanimously-recommends-approval (last accessed November 14, 2017).

Gilead. Press release: Gilead sciences to acquire Kite Pharma for $11.9 billion. www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion (last accessed November 14, 2017).

Dimension Therapeutics. Press release: Ultragenyx and Dimension announce expiration of Hart-Scott-Rodino waiting period for Ultragenyx's acquisition of Dimension. http://investors.dimensiontx.com/phoenix.zhtml?c=254192&p=irol-newsArticle&ID=2311718 (last accessed November 14, 2017).